Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Single-Arm Clinical Study of Recakimab for Lorlatinib-Induced Hypercholesterolemia / Mixed Hyperlipidemia

NCT07674368 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT07674368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07674368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Single-Arm Clinical Study of Recakimab for Lorlatinib-Induced Hypercholesterolemia / Mixed Hyperlipidemia
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
July 10, 2026
Completion date
August 1, 2028
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk fusion-positive non-small cell lung cancer